UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010196
Receipt number R000011944
Scientific Title Study of the safety and efficacy of tolvaptan for fluid retention symptoms of right heart failure due to pulmonary hypertension
Date of disclosure of the study information 2013/03/10
Last modified on 2015/09/09 11:09:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of the safety and efficacy of tolvaptan for fluid retention symptoms of right heart failure due to pulmonary hypertension

Acronym

Tolvaptan for right heart failure due to pulmonary hypertension

Scientific Title

Study of the safety and efficacy of tolvaptan for fluid retention symptoms of right heart failure due to pulmonary hypertension

Scientific Title:Acronym

Tolvaptan for right heart failure due to pulmonary hypertension

Region

Japan


Condition

Condition

pulmonary hypertension

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To observe how the administration of tolvaptan improve symptomatic fluid retention in patients with fluid retention symptoms of right heart failure due to pulmonary hypertension.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The usage dose of loop diuretics.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The administration of tolvaptan

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Chronic right heart failure due to pulmonary hypertension
2) Physical findings of fluid retention
3) Loop diuretic administration of furosemide 60mg in a day
4) Written informed consent is obtained

Key exclusion criteria

1) Systolic blood pressure is less than or equal to 70mmHg
2) There is a history of hypersensitivity for similar compounds (such as hydrochloride Mozabaputan) components or tolvaptan
3) Anuria
4) A subject is difficult to feel thirst or water intake
5) Hypernatremia
6) There is a possibility that a subject is pregnant or pregnant women
7) Hepatic coma
8) There is a history of hypersensitivity to sulfonamide derivatives
9) Tolvaptan has been administered from admission to registration
10) Acute coronary syndromes
11) Scheduled to perform coronary angioplasty during follow-up period
12) Physicians and other staff have been deemed inappropriate for registration of this study

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yuichi Tamura

Organization

Keio University School of Medicine

Division name

Department of Cardiology

Zip code


Address

35 Shinanomachi, Shinjuku, Tokyo, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Keio University School of Medicine

Division name

Department of Cardiology

Zip code


Address


TEL

03-5843-6702

Homepage URL


Email



Sponsor or person

Institute

Department of Cardiology, Keio University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Department of Cardiology, Keio University School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

慶應義塾大学病院


Other administrative information

Date of disclosure of the study information

2013 Year 03 Month 10 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

http://erj.ersjournals.com/content/46/1/283.extract

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 11 Month 01 Day

Date of IRB


Anticipated trial start date

2013 Year 03 Month 10 Day

Last follow-up date

2014 Year 05 Month 31 Day

Date of closure to data entry

2014 Year 08 Month 31 Day

Date trial data considered complete

2014 Year 10 Month 30 Day

Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 03 Month 09 Day

Last modified on

2015 Year 09 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011944


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name